Abstract Library

#4494 Efficacy and safety of surufatinib in combination with CAPTEM for patients with advanced G2/G3 NETs: Updated results from a single-arm, phase II study

Introduction: Limited options exist for advanced G2/G3 NETs. While combined anti-angiogenic and chemotherapy has shown improved effect, the efficacy of surufatinib combined with CAPTEM for NETs remains under-explored.

Conference:

Presenting Author: Wang W

Authors: Wang W, Liu Z, Yang X, Xue Z, Wei C,

Keywords: g2/g3 net, surufatinib, captem,

#4490 Parietal cell-selective Slc26a9 deletion in mice causes gasdermin D mediates mitochondrial damage and pyroptosis, which is the key event to induce autoimmune gastritis

Introduction: Autoimmune gastritis (AIG) is the basis of gastric malignancy, including neuroendocrine tumour (NET) and gastric cancer (GC). We reported that Slc26a9 is highly expressed in parietal cells (PCs), and its deficiency caused GC.

Conference:

Presenting Author: Liu X

Authors: Ji B, Deng Z, Ma Z, Li T, Tuo B,

Keywords: Slc26a9, autoimmune gastritis, Pyroptosis, gastric mucosal immunity remodelling,

#4414 Impact of chromogranin A expression on clinicopathological characteristics and prognosis in patients with gastrointestinal tumours exhibiting neuroendocrine differentiation

Introduction: Pathological diagnosis of neuroendocrine differentiation (NED) relies on histomorphological assessment and specific markers, including chromogranin A (CgA) and synaptophysin (Syn). Previous studies indicate that tumours with a high proportion of CgA (+) exhibit increased malignancy and aggressiveness in neuroendocrine tumours, suggesting that CgA may serve as a prognostic marker.

Conference:

Presenting Author: Liang T

Authors: Wang W, Jiang K, Liu X, Zhao L, Yu Z,

Keywords: neuroendocrine differentiation, gastric cancer, colorectal cancer, chromogranin A,

#4395 Mechanisms of drug resistance in neuroendocrine tumours: A basic research study

Introduction: Neuroendocrine tumours (NETs) often show resistance to chemotherapy and targeted therapies, leading to treatment failure. However, the molecular mechanisms underlying this resistance remain poorly understood.

Conference:

Presenting Author:

Authors: Xu L, Yu P, Chen J, Ye M, Xue B,

Keywords: Neuroendocrine tumour, drug resistance, mTOR, PI3K/AKT, tumour microenvironment, chemotherapy,

#4382 Sensitivity of endoscopic ultrasound in detecting small gastrointestinal neuroendocrine tumours

Introduction: Small gastrointestinal neuroendocrine tumours (GI-NETs) are often difficult to detect using conventional imaging modalities, leading to delayed diagnosis and suboptimal treatment outcomes. Endoscopic ultrasound (EUS) has emerged as a promising tool for the early detection and precise localisation of these tumours. However, its sensitivity in identifying small lesions remains to be thoroughly evaluated.

Conference:

Presenting Author:

Authors: Xu L, Ye M, Xue B, Tang Q,

Keywords: Endoscopic ultrasound, small gastrointestinal neuroendocrine tumour, early detection, imaging modalities,